Composition and method of application in cartilage involvements

FIELD: medicine, veterinary science.

SUBSTANCE: method for correction of cartilage pathologies in animals involves introduction to an animal of a cartilage pathology reducing, effective and nontoxic amount of a combination of at least one sulphur amino acid and manganese where at least one sulphur amino acid is chosen from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, Dl-cysteine, D-cystine, L-cystine, Dl-cystine, alpha-hydroxy-analogue of methionine, beta- hydroxy-analogue of methionine, manganese methionine and mixtures thereof. The same combination of at least one sulphur amino acid and manganese is introduced to an animal for prevention of cartilage degradation, and also added to the composition and set applicable in correction of cartilage pathologies, reduction of cartilage pathologies or prevention of cartilage degradation in animals.

EFFECT: group of inventions allows essentially improving the condition of animals in cartilage involvements.

21 cl, 8 tbl, 4 ex

 

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority of Patent Applications in the United States with a serial number 11/199350, filed August 8, 2005, which is partially continuing application and claims the priority of Patent Applications in the United States with a serial number 10/774781, filed February 9, 2004, which claims the benefits of PCT Application no PCT/US05/04274, filed February 9, 2005, the description of which is included in the present invention by this reference.

The LEVEL of TECHNOLOGY

The technical field to which the invention relates

In General, this invention relates to compositions and methods for improving the condition of the joint in animals and, in particular, to the use of sulfur-containing amino acid and manganese to reduce cartilage pathologies in animals.

Description of the prior art

Almost all the joints have cartilage. Cartilage is of great importance in animals to provide flexibility, compressibility under pressure, softening, elasticity, range of motion and smoothness of movement in the joints. Joints with cartilage, are the fingers and feet, neck, knee, hip, shoulder and the like. Animals can suffer from a wide range of diseases that affect the cartilage, which reduces the flexibility of the joint, compressibility and often inflammation of a joint and/or tissue surrounding the her joints. Then this animal is essentially lost the function of the joint is the pain.

U.S. patent No. 5587363, Henderson provides a composition for the protection, treatment and repair of connective tissues in humans and animals and the treatment of connective tissues in humans and animals by administration of a composition. The composition comprises the amino sugar and glycosaminoglycans. U.S. patent No. 6255295, Henderson provides a composition for the protection, treatment and recovery and reduce inflammation of the connective tissue in mammals and method of protection, treatment and repair of connective tissue in mammals by introduction of this composition. The composition includes at least two compounds selected from s-adenosylmethionine, amino sugar and connections, such glycosaminoglycan. The composition optionally contains manganese and, optionally, the composition includes methyl donors and cofactors of methyl donors. U.S. patent No. 6271213, Henderson provides a composition for the protection, treatment and recovery, and reduce inflammation of the connective tissue in mammals and method of protection, treatment and repair of connective tissue in mammals by introduction of this composition. The composition includes at least two compounds selected from s-adenosylmethionine, amino sugar and a link is, like glycosaminoglycan. The composition optionally includes manganese and, optionally, the composition includes a donor of methyl groups and cofactors donor of methyl groups. U.S. patent No. 5952367, Pak, provides a method of treating pain caused by tendonitis, arthritis and the like, includes the introduction of an effective amount of a nonsteroidal anti-inflammatory drugs and ingestion doses of methionine and sugar combination.

Kroger and others (1999) the Effect of Tryptophan plus Methionine-5-Azazytidine and Methotrexate on Adjuvant Arthritis of the Rat; Gen. Pharm. 33:195-201 reported that treatment with a combination of tryptophan and methionine stimulates the latter reaction. However, treatment with the two drugs, 5-azacytidine and methotrexate, in combination with tryptophan and methionine undoubtedly reduced the development of adjuvant arthritis and this effect is stronger than effect-azacytidine or methotrexate separately. Agency for Health Care Research and Quality (2002) Evidence Report Technology Assessment No. 64 reports that in the literature were identified studies that included a meta-analysis of the effectiveness of S-adenosyl-L-methionine (SAMe) in reducing pain in osteoarthritis. The results demonstrated that when compared with non-steroidal anti-inflammatory drug therapy, the SAMe treatment was not associated with statistically significant differences in the results of the Ah. However, one randomized clinical trial has shown effective value of 0.20 in favor of SAMe, compared with placebo, thus reflecting the reduction of pain in osteoarthritis. Johnston (1997), Orthoarthritis. Veterinary Clinics of North America; Small Animal Practice 27:699-720 reports that osteoarthritis is a slowly progressive disease of the synovial joints, which affects about 20% of the population of dogs over one year of life. A disease of the joints characterized by loss of balance between synthesis and degradation of components of the articular cartilage, leading to further destruction of the articular cartilage, remodeling of the underlying bone, the formation of bone growth and varying degrees of synovitis. Martinez and others (1997) Acquired conditions that lead to osteoarthritis in a dog. Veterinary Clinics of North America: Small Animal Practice; 27:759-775 reported that some of the most frequent causes of secondary osteoarthritis observed in animal-companions - is rupture of the anterior cruciate ligament, cutting osteochondritis, fragmented the coronal ridge and hip dysplasia. Other examples of diseases that affect the cartilage, include, but are not limited to, osteoarthritis, synovitis, bacterial purulent arthritis, psoriatic an osteoarthropathy, subchondral cystic lesions, visit, angular deformity of the limbs and deformity of the cuboid bone.

With age, the biggest dog develops arthritis. The large breed dogs are more prone to arthritis due to their increased mass and/or genetic predisposition. Large dogs are not the only animals with an increased risk of developing arthritis and other diseases of cartilage. Hardie and others (2002) Radiographic evidence of degenerative joint disease in geriatric cats. JAVMA 220(5):628-632 report that arthritis and other degenerative joint diseases were widely detected in dogs, and it was shown that such diseases predominate in cats. Other animals with an increased risk of development of diseases affecting cartilage, include, but are not limited to, mammals such as dogs, cats, horses, goats, sheep, pigs, cows, humans and other primates, and birds, including turkeys and chickens.

Known methods of reducing cartilage pathologies in animals are of limited effectiveness. There is therefore a need for new methods and compositions for treatment, prevention or correction of such conditions in animals.

The INVENTION

The present invention provides compositions and methods of improving the condition of the joint. Thus, various embodiments of provide ways to reduce the pathology of cartilage in animals, including introduction to the animal an effective amount of a combination of at least one serosal Rasa amino acids, and manganese.

Various embodiments provide methods of preventing degradation of the cartilage in animals, including introduction to the animal an effective amount of a combination of at least one sulfur-containing amino acid and manganese.

Different ways to provide compositions suitable for systemic injections of the animal, including reducing the pathology of cartilage or warning pathology of cartilage effective amount of a combination of at least one sulfur-containing amino acid and manganese. Various embodiments of provide food, which include a combination of at least one sulfur-containing amino acid and manganese in amounts effective to improve the condition of the joints of the animal.

Additional applications of various embodiments will become apparent from the detailed description presented below.

DETAILED description of the INVENTION

Different variants of the invention provide compositions and methods of improving the condition of the joint in animals and, in particular, animal companions such as dogs and cats. Description of specific examples, as pointed out different ways of implementation, are intended for illustration only and are not intended to limit the scope of the different versions. In addition, the enumeration of the numerous embodiments of the claimed who's property is not intended to exclude other embodiments, having additional properties, or in other embodiments, combining different combinations of the stated properties.

All literature and similar materials cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and web pages on the Internet, regardless of the format of such literature and similar materials, specifically totally incorporated by reference for any purpose to the extent permitted by law. If one or more of the combined sources of literature and similar materials different from or contradicts this application, including, but not limited to defined terms, use of terms, described techniques, or the like.

Cartilage consists of a living tissue that constantly breaks down and is replaced. However, the damage, the pressure on the joints and the aging process can damage the cartilage, often without any obvious signs until such time as it becomes a lot of damage. Cartilage is a substance that 65-80% consists of water. The remaining part consists of three other components: collagen, chondrocytes and proteoglycans. Collagen gives the cartilage its ability to mitigate shocks and elasticity, while proteoglycans are larger molecules that give cartilage its ability, the institutional capacity to stretch and then back to normal in response to movement. However, as with all substances, collagen and proteoglycans age. The chondrocytes remove old proteoglycans and collagen and produce new ones. These components, along with water, are working together to take care of the level of healthy cartilage and more free movement in the joints. If any of these components decreases, the cartilage may break down and begin to develop osteoarthritis.

Osteoarthritis mainly affects the articular cartilage, a smooth brilliant surface, which serves as a lining of the bone in the joint. The function of cartilage is to provide cushion and reduce friction, due to the fact that the slip joint. When osteoarthritis stonechats and damaged cartilage, which will collapse, becoming rough and eroded. Cartilage and bone are destroyed, because the bones RUB against each other, and the deformation is, if one side of the joint is weakened more than the other side. If the wear and tear of the cartilage is great, when it is used or even while relaxing in the affected joint may be a sharp pain.

When attempting to improve such conditions as described above, used a variety of substances. Such attempts have covered the use of supplements of glucosamine, chondroitin and chondroitin sulfate in the treatment of arthritis. Glucosamine is a component of proteoglycans, which retains fluid in the cartilage Chondroitin - this is another component of proteoglycans.Green lipped canaliculatais a rich source of glycosaminoglycans (GAGs). Unfortunately, these GAGs are poorly absorbed when taken orally. Green lipped may be useful in the treatment of arthritis, but the observed benefit may be more from its natural anti-inflammatory effect than from the direct absorption of glycosaminoglycans. Creatine plays an important role in the transformation of glucose into muscle energy and may have value in improving muscle strength and help to ensure that older animals feel more energetic. Methylsulfonylmethane (MSM) has anti-inflammatory action, which slows down the development of arthritis and of course reduces pain; other substances that are usually used by people, but can also be used in the treatment of animals, not people, including aspirin, anti-inflammatory agents such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions.

In various embodiments, the implementation of the compositions and methods of improvement, treatment, prevention and/or facilitate the above-described conditions include introduction to the animal a combination of at least one sulfur-containing amino acid and manganese.

The term "sulfur-containing amino acid(you)" means sulfur-containing amino acid and its proizvodi the E. The term "monitoring cartilage" means improvement, treatment, prevention and/or alleviation of at least one disease, damaging the cartilage and/or animal positive effects on cartilage. The term "monitoring cartilage covers preventive measures in relation to animal with latent disease that affects the cartilage, predisposition, either hereditary or otherwise, to a disease that affects the cartilage, or precautionary measure at any time during the life of the animal to strengthen cartilage, preventing pathologies cartilage, improve joint mitigate degradation of joints with age, or for the prevention of arthritis or other diseases affecting the joints. Illustrative examples of the positive effects on cartilage cover increased flexibility, recovery of damages, reduction of inflammation, improved mobility, strengthen cartilage, reduction of pathologies and/or warning of any reduced flexibility and/or mobility, weakness and/or degradation of cartilage pathologies and/or damage, inflammation or disease, damaging the cartilage and the like. Illustrative examples of such diseases affecting cartilage, cover osteoarthritis, rheumatoid arthritis, osteoarthritis, degenerative joint disease, synovitis, the tank is arianny purulent arthritis, psoriatic the authors and the like.

The animal can be a human or may not be human. In various embodiments, the implementation of the animal may be a vertebrate, such as fish, bird, reptile or mammal. Illustrative of mammalian animal may be representative of a squad of raptors, including, without limitation, dogs and cats. In various embodiments, the animal may be an animal companion. In the present invention "animal companion" is an individual animal of any species kept as a pet in caring for the person, or any individual animal from a number of species that are widely domesticated as Pets, including dogs (Canis familiaris) and cats (Felis domesticus), regardless of whether each particular animal solely for communication or in part. Thus, in the present invention "animal companion" cover working dogs, cats, farmed for rodent control, etc, as well as indoor dogs and cats.

Despite these different ways of implementation, it becomes clear that these methods are also suitable, as a rule, for other mammals, including marine mammals, non-human, such as primates, non-human (e.g., monkeys, chimpanzees, etc.) animal companion and working animals (such as horses etc), farm animals (such as goats, sheep, pigs, cattle etc) and wild animals and animals in zoos (e.g., wolves, bears, deer, lions, tigers, giraffes, elephants and so on). Various embodiments also generally suitable for use on animals that are not mammals, such as an animal companion, farm animals and animals in zoos, and wild birds (including, for example, songbirds, parrots, ducks, geese, chickens, turkeys, ostriches and so on).

The term "food" means food and drink regularly consumed by the animal, and may include daily diet, provide a caring person. Daily diet may contain any appropriate food composition, which provides sufficient power animal, for example a standard food composition for dogs can contain about 10 to 30% fat, from about 22 to 44% by weight protein and about 10% total dietary fiber. In another example, the standard food composition for cats can contain fat, from about 10 to 30% by weight, and protein, from about 30 to 45% by weight. However, you do not need specific proportions or percentages of these or other nutrients. A nutrient is any nutritional comp the element, which helps to sustain life. The following represents examples of nutrients that are important for the health of the animal companion:

In various embodiments, the implementation of the sulfur-containing amino acid and manganese may be introduced to an animal, preferably to the needy in this introduction, at least one of a variety of ways, such as oral, parenteral, and the like, although oral is preferred. In various embodiments, the implementation of the sulfur-containing amino acid and manganese may be introduced in the wet or dry food composition, or be included in it, either on the surface of any food component, for example, through sputtering or deposition on it. In various embodiments of sulfur-containing amino acid and manganese may be present in the diet in the form of a snack, Supplement, food, or liquid part of the diet, such as water or other liquid. In different versions of sulfur-containing amino acid and manganese may be introduced as a powder, solid or liquid, including a gel. In various embodiments, the implementation of the sulfur-containing amino acid and manganese may be administered orally in the pharmaceutical dosage form such as capsule, tablet, drips, syringes and the like, and such dosage form, sulfur-containing amino acid and manganese may be present in powder form or liquid, such as a gel. Can be used on any of the usual pharmaceutical carriers, such as water,glucose, sucrose and the like together with the sulfur-containing amino acid and manganese. In various embodiments of sulfur-containing amino acid and manganese may be provided in liquid or in pharmaceutical dosage forms such as capsules, tablets, pills, liquids, or even parenteral be injected through a syringe. Although examples of joint introduction, the sulfur-containing amino acid and manganese may be introduced separately, then there is something in the food composition and something in a liquid or a standard dosage form, for example. Typically, the sulfur-containing amino acid and manganese should be introduced, at least, and preferably concomitantly in the same medium.

An important aspect is that the animal is provided an effective amount of sulfur-containing amino acid and manganese, to ensure a positive effect on cartilage. Positive effects on cartilage may include one or more of the following: increase flexibility, recovery of damages, reduction of inflammation, improved mobility, strengthen cartilage, reduction of pathologies and/or prevention of any reduction of flexibility and/or mobility, weakness and/or degradation of cartilage pathology and/or damage, inflammation or disease, damaging the cartilage and the like. The preferred method is introduced which is oral and combined with the feed suitable for animal consumption.

With the introduction of the feed to the sulfur-containing amino acid and manganese may be introduced in the form of a composition. Such a composition may be a food composition, additive, food or a toy, it is noted that some, but not all, supplements, treats and toys are food compositions. The food compositions are introduced to the animal during feeding. If the animal is an animal companion, the food composition is usually a composition, which dietologicheskie adapted for feeding such animal. Food composition adapted so called in the present invention "pet food". Pet food can be more specific and adapted to the special dietary needs of dogs or cats, or for some subpopulations, such as dogs large breed adult dogs or cats, older dogs or cats, old dogs or cats, etc.

In various embodiments, the implementation of the food composition, comprising sulphur-containing amino acid and manganese, provides substantially complete nutritious diet intended animal to the recipient. "Wholesome nutritious diet is a diet that includes enough nutrients to maintain normal healthy is the first animal on this diet.

In various embodiments food composition comprising a sulfur-containing amino acid and manganese may be an additive, the additive is used with other food composition for improving the nutritional balance or diet quality in General. Such supplements comprise compositions that are used undiluted as a Supplement to other products offered freely consumption with other parts of the daily diet of the animal that are available to an animal individually, or diluted and mixed with the usual food of animal to obtain substantially complete nutritious diet. Alternatively, the additives may be in a form different from the food composition, for example in a dosage form that is similar to the pharmaceutical, including, for example, powders, liquids, syrups, capsules, tablets, pills, etc.

In various designs additive comprising an effective amount of sulfur-containing amino acid and manganese, also contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In various embodiments, the implementation of an additive comprising an effective amount is about sulfur-containing amino acid and manganese, moreover contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions. In different versions of the additive comprising an effective amount of sulfur-containing amino acid and manganese, in addition, contain an effective amount of at least glycine or Proline.

In various embodiments, the implementation of the food composition, comprising sulphur-containing amino acid and manganese may be a delicacy. Goodies include, for example, compositions that give the animal as a reward or to attract the animal to the food in time, unusual for feeding. Treats for dogs that are food compositions that have at least some nutritional value, include, for example, dry biscuits for dogs. Alternatively Goodies can be substantially non-nutrient (except in those cases when the sulfur-containing amino acid and manganese may be considered as nutrients). The composition comprising the sulfur-containing amino acid and manganese may itself be a treat, can be applied to an existing treat, or both.

In various embodied the s composition, including sulfur-containing amino acid and manganese may be a toy, which is adapted for oral use in animals. Toys include, for example, razzhevyvanie toys, such as artificial bones for dogs. The composition comprising the sulfur-containing amino acid and manganese may form a coating on the surface of the toy or on the surface of a component of the toy, can be incorporated partially or fully through the thickness of the toy, or both. Currently sells a wide range of suitable toys, including partially usable toys (for example, toys that contain plastic components) and fully usable toys (for example, Nedelina leather and various artificial bone). Toys suitable for human use and not a man, especially an animal companion, farm animals and animals kept in the zoo, and more particularly to the use of a dog, a cat or a bird.

Various sulfur-containing amino acids and their derivatives are applicable in different variants of implementation and they include, but are not limited to, D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, DL-cystine, S-adenosylmethionine, alpha - and beta-hydroxy-analogs of methionine, their racemizes the e mixture and mixture of amino acids, as described, and the like. In various embodiments of sulfur-containing amino acid can be provided to the animal itself or of course, you can log in foods such as fish meal, corn gluten meal, flour of birds, casein, methionine manganese (chelate), and the like.

Manganese may be given to the animal in various forms, including, for example, manganese sulfate, manganese oxide, manganese dioxide, manganese carbonate, manganese chloride, Proteinate manganese, manganese chelate, manganese monoxide, manganese methionine, and the like.

In various embodiments, the amount of sulfur-containing amino acid and manganese, which should be used in combination to cause the effect(s)can vary significantly. In various embodiments, implementation of the minimum number of sulfur-containing amino acid is more than about 1.2% by weight, preferably more than about 1.5% by weight and more preferably more than about 1.8% by weight. In various embodiments, the minimum amount of manganese is more than about 50 ppm (ppm), preferably more than about 65 ppm, and more preferably more than about 100 ppm. In different versions the exact amount of sulfur-containing amino acid and manganese may be introduced in the usual diet food food every day ilita same day number can be entered animal to treat or Supplement every day. In various embodiments, the implementation may use a combination of these approaches or any other dosing methods up until is provided an effective amount of sulfur-containing amino acid and manganese. The maximum number of sulfur-containing amino acid and manganese is the largest number that can be considered as safe, such as less than LD50 sulfur-containing amino acids or manganese or equal. Examples of such quantities for amino acids comprise not more than about 5.0 percent by weight to 4.0% by weight and 3.0% by weight on the same principle as for the minimum quantity. Examples of such amount margency cover no more than about 200 ppm, preferably not more than about 175 ppm and more preferably not more than about 150 ppm on the same principle as for the minimum quantity. In various embodiments, the composition comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatefatty acids omega-3, omega-6 and mixtures thereof. In different versions composition that includes effectiveagainst sulfur-containing amino acid and manganese, also contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions. In various embodiments, the implementation of a composition comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least glycine or Proline. In various embodiments, the minimum amount of glycine is about 1.4%, preferably about 1.6% by weight and more preferably about 2.0 percent by weight. In different versions the minimum number of Proline is about 1.45% by weight, preferably about 1.6% by weight and more preferably about 2.0 percent by weight.

In various embodiments, the implementation of the daily diet includes an effective combination of sulfur-containing amino acid and manganese. In various embodiments of the daily ration comprises at least about 3.5 g/mcal of sulfur-containing amino acids. In different versions of the daily diet contains at least about 50 ppm to megacalorie manganese. In some embodiments, the implementation of the daily diet includes at least about 3.5 g/mcal sulfur-containing acid and at least about 50 Millionnaya on megacalorie manganese. In various embodiments daily diet includes an effective amount of sulfur-containing acid and manganese further contains an effective amount of at least glycine or Proline. In different versions of the daily diet contains at least about 4.0 g/mcal of glycine. In various performances daily diet includes at least about 4.0 g/mcal of Proline. In various embodiments, the implementation of the daily ration comprises at least about 4.0 g/mcal of glycine and at least about 4.0 g/mcal of Proline. In various embodiments of the daily diet, which includes an effective amount of sulfur-containing amino acid and manganese further contains at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In different versions of the daily diet, which includes an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions.

Various embodiments of HC is primarily a way to restore the cartilage of the animal. In various embodiments, this method comprises feeding the animal a food composition comprising a sulfur-containing amino acid in the amount of at least about 1.2% by weight and manganese in the amount of at least about 50 ppm of dry matter per day. In various implementations, the method comprises feeding the animal a food composition comprising the sulfur-containing amino acid in the amount of at least about 1.8% by weight and manganese in the amount of at least about 100 ppm of dry matter per day. In a different implementation, the method comprises feeding the animal a food composition comprising the sulfur-containing amino acid in an amount of about 1.2% by weight to about 3.6% by weight and manganese in the amount of from about 50 ppm to about 200 ppm of dry matter per day. In various embodiments, the method comprises feeding the animal a food composition comprising an effective amount of sulfur-containing amino acid and manganese, in addition, it contains an effective amount of at least glycine or Proline. In different versions the minimum amount of glycine is about 1.4%, preferably about 1.6% by weight and more preferably about 2.0% by weight. In various embodiments, the implementation of the food the song includes an effective amount of sulfur-containing amino acid and manganese, in addition, it contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In various embodiments food composition comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions.

In various implementations, the method includes providing an animal a daily diet containing an effective amount of sulfur-containing amino acid and manganese. In various embodiments, the effective amount of sulfur-containing amino acid and manganese may be added in the form of supplements to the daily diet compiler mixtures or manufacturer, or person caring for the animal. In various embodiments daily diet includes at least about 3.5 g/mcal of sulfur-containing amino acids. In different versions of the daily diet contains at least about 50 ppm to megacalorie manganese. In some embodiments, is sushestvennee daily diet includes at least about 3.5 g/mcal sulfur-containing acid and at least about 50 ppm to megacalorie manganese. In various embodiments of the daily diet contains an effective amount of sulfur-containing acid and manganese, in addition, it contains an effective amount of at least glycine and Proline. In different versions of the daily diet contains at least about 4.0 g/mcal of glycine. In various embodiments, the implementation of the daily diet contains at least about 4.0 g/mcal of Proline. In various embodiments of the daily diet contains at least about 4.0 g/mcal of glycine and at least about 4.0 g/mcal of Proline. In different versions of the daily ration comprises an effective amount of sulfur-containing amino acid and manganese, in addition, it contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In various embodiments, the implementation of a daily diet containing an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions.

In RA the personal lives daily diet includes increased amounts of sulfur-containing amino acid and manganese, that improves the condition of the joints of the animal companion. In various embodiments, the sulfur-containing amino acid and manganese is added to animal feed. In various embodiments, the implementation of the sulfur-containing amino acid and manganese may be added to animal feed before feeding animal compiler mixtures or manufacturer, or the person looking after the animals. In such embodiments, the manganese and sulfur-containing amino acid can be added during the preparation of animal feed, which is then packaged and provided to customers. Such preparation may include extrusion, canning, baking and the like, or any other method or process of manufacture of pet food, which is known in this field. In various embodiments, the sulfur-containing amino acid and manganese may be provided by a natural source, like a animal or vegetable component, or sulfur-containing amino acid and manganese may be provided by a source of artificial origin, or sulfur-containing amino acid and manganese may be provided by a mixture of natural and artificial sources.

In the preparation of canned or wet food compositions powdered protein tissue of animals and birds mixed with other ingredients including fish the Il, cereal grains, other food balancing ingredients, additives for special purposes (for example, a mixture of vitamins and minerals, inorganic salts, cellulose and beet pulp, fillers and the like), and add water sufficient for processing. These ingredients can be mixed in a vessel suitable for heating during homogenization of the components. The heated mixture can be carried out in any suitable way, as, for example, by submitting an open steam or through the use of a vessel equipped with a heat exchanger. After adding the last ingredient, the mixture is heated to a temperature in the range of from about 50°F to about 212°F, for example from about 70°F to about 140°F. Temperatures outside this range generally acceptable, but may be commercially impractical without the use of other techniques. After the material is heated to the appropriate temperature, it usually takes the form of a viscous liquid. Viscous liquid is poured into cans. Overlaps the lid and the container is hermetically closed. Then closed tin can is placed in the standard equipment designed for the sterilization of bottles. This is usually completed by heating to a temperature of more than about 230°F during the relevant time, that depends, for example, by temperature and composition.

Alternative food compositions can be prepared in dry form, using traditional surgery. Usually the dry ingredients, including, for example, animal protein, vegetable protein, grain, etc., grind and mix together. Then add the wet or liquid ingredients, including fats, oils, animal protein, water, etc. and mixed with the dry mixture. Then this mixture is processed into large pieces or similar dry pieces. Often a major piece formed using an extrusion process in which a mixture of dry and wet ingredients are machined at high pressure and temperature and is forced through small holes and cut into large pieces using a rotating knife. Then wet a large piece of dried and, if desired, cover one or more membranes, which may include, for example, flavors, fats, oils, powders and the like. Also a large piece can be obtained from the paste using baking process, is preferable to extrusion, where the paste is placed in a mold prior to dry-heat treatment.

Treats can be prepared, for example, by extrusion or baking, similar to those described above for the dry food composition. Can also use the I other processes, to either apply a composition comprising sulfur-containing amino acid and manganese on the outer part of the form of treats or upload into the form of Goodies. Toys that are applicable in the present invention, illustrative can be prepared by coating toys composition comprising sulfur-containing amino acid and manganese.

In various embodiments, the implementation of the animal can be administered an effective amount of sulfur-containing amino acid and manganese. In various embodiments of sulfur-containing amino acid and manganese may be present in the capsule in order to give the animal. In various designs an effective amount of sulfur-containing amino acid and manganese may be in powder or crystalline form, which can be added to food animal or directly give the animal. In various embodiments, the implementation of the sulfur-containing amino acid and manganese may be an additive, which is added to food animal or to daily diet. Such supplements comprise compositions that are fed undiluted as a Supplement to other food products offered in the free consumption with other parts of the daily diet of the animal that are available to the animal itself, or diluted and mixed with the usual food of animal to get to a large degree the Yeni wholesome nutritious diet. Alternatively, the additive may be in a form different from the food composition, for example in a dosage form that is similar to the pharmaceutical, including, for example, powders, liquids, syrups, capsules, tablets, pills, etc.

In various embodiments, the implementation of an additive comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In various embodiments additive comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions. In various designs additive comprising an effective amount of sulfur-containing amino acid and manganese, also contains an effective amount of at least glycine or Proline. In various embodiments, the implementation of the animal feed composition includes an effective amount of sulfur-containing amino acid and manganese and other think is that food components. In various embodiments the effective amount of sulfur-containing amino acid and manganese may be administered to an animal via a syringe. In various embodiments, the dose comprises at least about 3.5 g/mcal of sulfur-containing amino acids. In various embodiments, the implementation of dose contains at least about 50 ppm to megacalorie manganese. In some embodiments, the dose comprises at least about 3.5 g/mcal of sulfur-containing amino acids and at least about 50 ppm to megacalorie manganese.

In various embodiments, the dosage comprising an effective amount of sulfur-containing acid and manganese further contains an effective amount of at least glycine or Proline. In some embodiments, the implementation of dose contains at least about 4.0 g/mcal of glycine. In various embodiments dose contains at least about 4.0 g/mcal of Proline. In some implementations, the dose comprises at least about 4.0 g/mcal of glycine and at least about 4.0 g/mcal of Proline. In various embodiments, the implementation of dose comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant, Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof. In various embodiments, the dose comprising an effective amount of sulfur-containing amino acid and manganese further contains an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatories, such as ibuprofen, COX-2 inhibitors and other drugs and pharmaceutical compositions.

Indicator of cartilage is the number of pathologies, visually observed in the cartilage. Other ways of detecting abnormalities of cartilage include MRI, CT scan and radiography. The greater the number of pathologies, the more it weakens the whole joint, which makes it more prone to disease or exacerbate pre-existing health condition. These diseases include arthritis (osteo and rheumatoid), degenerative disc disease, degenerative joint disease, synovitis, bacterial purulent arthritis, osteoarthropathy and, among other things, psoriasis. Visualized pathology of cartilage focus mainly on damage, destruction and pathological growth.

In another aspect the present invention provides methods of transmitting information or instructions to correct or reduce the pathology of cartilage and prevent the degradation of cartilage in animals. Funds transfer and the formation contain a document digital data storage device, optical storage device, audiopresenter or visual display containing the information or instructions. The message preferably represents a displayed web site or brochure, product label, the liner into the packaging, the advertising message or visual display containing the information or instructions. Suitable information comprises one or more of (1) methods and techniques of administration of the compositions and methods of the present invention, (2) details about the side effects, if it is caused by the use of the present invention, in pure form or together with other drugs, and (3) contact information for patients to use if they have a question about the invention and its application. Suitable instructions cover the dosage, quantity in the introduction and the frequency and route of administration. A means of sharing information used for instructing on the benefits of using the present invention and exchange approved methods of application of the present invention.

The term "individual package" means that components are physically associated with one or more containers or in them, and are treated as a unit for manufacture, distribution, sale, or use the attachment. Containers include, but are not limited to, bags, boxes, bottles, plastic bags, connected by staples or otherwise attached components, or combinations thereof. A single package may be containers for individual food compositions that are physically associated such that they are treated as a unit for manufacture, distribution, sale or use. The term "virtual package" means that the components of the set are connected by means of instructions on one or more physical or virtual component set that instruct the consumer how to obtain other components, for example in a bag containing some component, and instructions that instruct the consumer to visit the website, find the recorded message, view a visual message or to find a caring man or instructor for instructions on how to use this set.

In an additional aspect, the present invention provides kits suitable for correction or reduction of cartilage pathologies or prevent the degradation of cartilage in animals. The kits contain in separate containers in a single package or in separate containers in a virtual package, which corresponds to the component set, the first component set comprising at least one serosoderjaschei the amino acid or manganese, and the second feature set that includes at least one of the following: (1) sulfur-containing amino acid (if sulfur-containing amino acid is not present in the first component set), (2) manganese (if manganese is present as a first component set), (3) other sulfur-containing amino acid, (4) food suitable for consumption by the animal, (5) at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidant,Green lipped canaliculatafatty acids omega-3, omega-6 and mixtures thereof, and (6) means for exchange of information or instructions for the treatment of diseases affecting cartilage, increase the flexibility of the cartilage, increasing the strength of the cartilage or prevent the degradation of cartilage in animals.

In other embodiments, implementation of sets, in addition, include one or more drugs, suitable for control of diseases, damaging the cartilage, increase the flexibility of the cartilage, increase the strength of cartilage or preventing degradation of cartilage, for example, an effective amount of at least one substance selected from the group consisting of aspirin, anti-inflammatory compounds, such as ibuprofen, COX-2 inhibitors and an effective amount of at least one sulfur-containing amino acids and IDA is of the like.

Usually the components of the kit are in a separate package in the package or one of the other components of the set, or in a virtual package that matches the type of the component set. If the set contains a virtual package, this set is limited to the instructions in virtual reality in combination with one or more other physical components of the set.

In a further aspect the present invention provides use of a composition comprising a combination of at least one sulfur-containing amino acid and manganese, for the preparation of medicines. In another, the invention provides for the use of such compositions for the preparation of drugs to reduce the pathology of cartilage or preventing degradation of cartilage in animals. Generally, medicines are prepared by mixing the compounds or compositions with fillers, buffers, binders, plasticizers, dyes, solvents, condensing agents, lubricating agents, fragrances, moisturizers and other ingredients known to the trained professionals that they are suitable for the production of medicines and preparation of recipe drugs that are suitable for administration to an animal.

This invention is not limited to particular methodology, protocols, and what eigentum, described therein, as they may change. Moreover, the terminology used is intended only to describe specific embodiments and is not intended to limit the scope of the present invention. In the present invention and in the accompanying claims forms singular cover plural references unless the context clearly does not prescribe otherwise. Similarly, the words "include", "contains" and "contain" should rather be interpreted inclusively, rather than exclusively.

If not defined otherwise, all technical and scientific terms, and any abbreviations used in the present invention, are the same values that are understood by the person skilled in the art. Although any of the compositions, methods, finished products or other tools or materials similar to those described in the present invention or the equivalent, may be used when applying the present invention, preferred compositions, methods, finished products or other tools or materials described in this invention.

All patents, patent applications, publications, and other references cited or referred to in the present invention included in the present invention by reference to the extent permitted by law. Discussion reference is intended only for the summation of the allegations made. 't done is any assumptions that any such patents, patent applications, publications or links, or any part of them, constitute relevant prior art for the present invention, and the right to dispute the accuracy and relevance of such patents, patent applications, publications and other references reserved.

EXAMPLES

This invention can be illustrated by the following examples. It should be understood that these examples are included only for the description and are not intended to limit the scope of the present invention, unless otherwise specified.

Example 1

Growing pigs (80 experimental animals) were used as an experimental model to determine the effect of methionine and manganese on the pathology of cartilage. The initial weight of the pigs is about 35 kg Each pig was placed separately in the paddock area of 5.2 quot with unlimited access to feed and water. Pigs were fed experimental forage within 60 days prior to the estimated total weight of about 130 kg

In meat production took the distal part of the right femur and measured the amount of damage and histopathological characteristics. The distal part of the right femur were fixed in formaldehyde and kept at room temperature for General observations. The joints were evaluated by the total amount of damage to the Pris is existing on the surface of the joint (including clinical damage, destruction of cartilage and areas of abnormal growth). Gross damage was confirmed by histopathological examination. Slices of tissue from the ventral load-bearing parts of the medial femoral condyle. Performance was assessed by 2X and 10X the micrographs to determine the number of cells and to confirm the pathological cartilage damage in the subchondral bone.

Table 1
Standard Components of Animal
ProteinsThe main element of body tissues, such as muscle, blood, skin, organs, hair and nails.
CarbohydratesProvide tissues with energy.
FatsFat absorb, accumulate and take vitamins to moisturize the skin and integuments, make healthy food for Pets is a wonderful taste and provide energy.
WaterThe most important nutrient for survival.
VitaminsHelp in maintaining the metabolism of the animal.
MineralsNecessary for healthy skin and coat, proper skeletal support and growth. Minerals are usually full of ingredients in pet food.
Table 2
The composition of the Investigated Feed
ControlSample 1Sample 2Sample 3
Corn71,0078,5071,0071,00
Soy flour18,703,3518,7018,70
Corn starch3,783,002,522,48
Choice White grease,00 1,003,003,00
Dical1,971,131,982,03
Limestone0,620,280,770,74
Sol0,430,310,550,55
L-lysine0,150,080,150,15
Vitamin Supplement0,100,100,100,10
Choline0,100,100,100,10
TM-additive0,100,100,100,10
Sulfate Mn0,02 0,02
Tryptophan0,03
Flour of birds12,00
DL-methionine0,041,031,03
Only100100100100
100% dry matter
ME, kcal/kg3604363436043604
Ca, %0,860,850,860,86
P %0,740,740,740,74
Na %0,220,220,220,22
Lysine, %0,970,960,970,97
TSAA, %0,580,601,711,71
Tryptophan, %0,200,200,200,20
Threonine, %0,660,700,660,66
Isoleucine, %0,650,650,650,65
Sulfur, ppm1664222941474238
Manganese, ppm41,3107,841,2127,4

Table 3
Analytical Studies of the Investigated Feed - Series 1
ControlSample 1Sample 2Sample 3
Crude protein17,32MT 18 : 3416,6316,93
Fat7,767,587,467,42
Fiber2,051,732,232,37
Methionine+Cystine0,700,721,511,78
Manganese46,481,243,4110,0

Table 4
Analytical Studies of the Investigated Feed - Series 2
ControlSample 1Sample 2Sample 3
Crude protein17,3818,4319,3017,94
Fat6,837,897,547,46
Fiber2,911,822,472,22
Methionine+Cystine0,680,781,611,56
Manganese41,896,842,2110,1

Table 5
The influence of Nutrients on the Pathology of Cartilage
ControlSample 1Sample 2Sample 3
Total damage2,382,251,380,88

The data show that the combination of increased amounts of sulfur-containing amino acids methionine and cystine and manganese statistically reduces the number of visually observable abnormalities of cartilage (e.g., damage and destruction), as shown on the Sample 3. The effect of the combination was greater than the effect of methionine and cystine in isolation, but the influence of manganese separately essentially had no effect. Sample 1 contains a lot of manganese, but approximately the same number of sulfur-containing amino acids that control. Sample 2 contains many sulfur-containing amino acids, but approximately the same amount of manganese as the control.

Example 2

Younger pigs (80 experimental animals) were used as experimental models to determine the effects of methionine and manganese on the pathology of cartilage. The initial weight of the pigs is about 35 kg Each pig was placed separately in the paddock area of 5.2 quot with unlimited access to feed and water the. Piglets were fed with experimental feed within 90 days prior to the estimated total weight of about 130 kg

Table 6
The effect of GAGs, Methionine, Manganese, Glycine and Proline on the Degradation of Cartilage in Growing Pigs
A. the impact of the Elements of the Structure of Cartilage on Whey the Matrix Metalloproteinases and the Concentration of Inhibitor
GAGsnoYesnononononoYes
Methionine0,300,341,430,300,300,301,431,38
Manganese41108128 414141128127
Glycine0,791,290,781,681,682,581,681,68
Proline1,141,291,141,692,231,691,691,68CV
The enzyme, mg/DL
MMP-34,653,985,436,61*** 5,15br4.61equal to 4.974,5045,67
MMP-8
MMP-11to 2.290,34*0,28*1,380,49*0,53*0,62***0,70***238,86
* Control vs. Treatment (P <.05)
** Control vs. Treatment (P <.01)
*** Control vs. Treatment (P <.10)
B. the impact of the Elements of the Structure of Cartilage on the Synthesis of Collagen
GAGsnoYes nononononoYes
Methionine0,300,341,430,300,300,301,431,38
Manganese41108128414141128127
Glycine0,791,290,781,681,682,581,681,68
Proline1,14 1,291,141,692,231,691,691,68CV
Collagen Type II120,43111,6289,76*105,4988,66*118,3891,34*103,729,3
CP2730,78764,03687,02733,99704,09726,14724,31707,0815,5
* Control in comparison with Leche is observed (P < .05)
** Control vs. Treatment (P <.01)
*** Control vs. Treatment (P <.10)
C. Influence of the Elements of the Structure of Cartilage in General and
Histological Pathology of Cartilage
GAGsnoYesnononononoYes
Methionine0,300,341,430,300,300,301,431,38
Manganese41108128414141128 127
Glycine0,791,290,781,681,682,581,681,68
Proline1,141,291,141,692,231,691,691,68CV
Rough
the damages.
Qty
2,381,29to 1.861,501,00*1,751,17*** 1,8998,97
Thickening,
mm
1,901,942,011,942,101,872,011,9312,10
* Control vs. Treatment (P <.05)
** Control vs. Treatment (P <.01)
*** Control vs. Treatment (P <.10)

These data demonstrate that the degradation of cartilage decreases, as evidenced by reduced activity of MMP-13 and decreased synthesis of collagen Type II (less intense repair cartilage). Result in reduced damage to the cartilage.

After 90 days, serum samples were collected to determine the activity of matrix metalloproteinases (MMP-13) and the activity of the synthesis of collagen Type 2. As shown by the above data, the combination of increased sulfur-containing amino acid and manganese corrects the cartilage that demonstrate improvement in activity of the enzyme MMP-13 and synthesis of collagen Type 2.

Example 3

In cats ranging in age from two to eight months is evaluated in the condition of the cartilage. Cats were divided into groups, and Group 1 was fed the control diet, Group 2 was fed food enriched in glycine and Proline, Group 3 was fed food enriched with methionine and manganese, and Group 4 were fed food enriched in glycine, Proline, methionine and manganese. Table 7 shows the data for the various components measured in the serum of cats in the study.

Table 7
The influence of Amino acids and Manganese on the condition of the Cartilage in Cats
TSSAGlycineGlycine/Proline
TheControlMnProlineTSSA/Mn
Glycine/mcal,
g/mcal
5,85,87,67,7
Proline/mcal,
g/mcal
5,15,06,66,6
Methionine/mcal, g/mcal1,63,31,53,3
Manganese/mcal, ppm/mcal4,1133,134,1333,09
D-pyridinoline6,87the ceiling of 5.60*6,536,72
Pyridinoline3,853,51the 3.653,38**
NTx10,6610,3511,4611,7
CTx13,1112,6713,0210,54***
Osteocalcin0,881,62**1,92***1,51
Specific bone
alkaline phosphatase
37,6637,4239,7939,25
*Differences between treatment and control at P <.10
** Differences between treatment and control at P <.17
*** Differences between treatment and control at P <.05

Example 4

The data in Table 8 illustrate the results of the study demonstrate that cartilage damage can be reduced in pups fed glycine, Proline, methionine and manganese.

Table 8
The influence of Amino acids and Manganese on the condition of the Cartilage in Dogs
Glycine/Proline
TheControlTSSA/MnP value
Glycine/mcal, g/mcal5,16,0
Proline/mcal, g/mcal4,25,0
Met the onin war/mcal, g/mcal1,33,5
Manganese/mcal, Ppm/mcal7,7033,54
CTx
Initial17,7814,840,31
Final9,437,90,10
Change-8,82-6,95
The change from beginning to end.
A value of P
0,010,01
The synthesis of Collagen Type II
Initial4585160,07
Final4454090,38
Change-13,5-1070,09
The change from beginning to end.
A value of P
0,720,01
MMP-13
Initial0,60,440,47
Final0,320,510,18
Change-0,280,080,17
The change from beginning to end.
A value of P
0,140,65

The words "include", "contains" and "contain" should rather be interpreted inclusively, rather than exclusively. Except when stated otherwise, all percentages listed in the present invention, represent the weight percent of the dry mass of the substance. The phrase "dry weight substances" means the concentration of a component in the composition after at the Alenia any moisture from the composition.

The examples and other embodiments of described in the present invention are illustrative and are not intended to be limiting in describing the full scope of devices, systems, compositions, materials and methods of these embodiments. Equivalent changes, modifications, variations of the specific embodiments, apparatus, systems, compositions, materials and methods may be implemented in the scope of various embodiments is essentially similar results. Such changes, modifications or variations should not be regarded as a departure from the essence and scope of various embodiments.

1. How to repair cartilage pathologies in animals, including the introduction of the animal reduces the pathology of cartilage, effective and nontoxic amount of a combination of at least one sulfur-containing amino acid and manganese, where at least one sulfur-containing amino acid selected from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, DL-cystine, alpha-hydroxy analogue of methionine, beta-hydroxy analogue of methionine, manganese methionine, and mixtures thereof.

2. The method according to claim 1, wherein the animal is a dog or a cat.

3. The method according to claim 1, in which the sulfur-containing amino acid and manganese are provided in the stern.

4. The method according to claim 1, in which the torus pathology of cartilage is chosen from the group consisting of osteoarthritis, rheumatoid arthritis, degenerative disc disease, degenerative joint disease, synovitis, bacterial purulent arthritis and psoriatic osteoarthropathy.

5. The method according to claim 1, further comprising an introduction to the animal an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidants, green lipped canaliculata, fatty acids omega-3, omega-6 and mixtures thereof.

6. The method according to claim 1, further comprising an introduction to the animal a composition containing reducing the pathology of cartilage, effective and non-toxic amount of at least glycine or Proline.

7. Method of preventing degradation of the cartilage of the animal, including the introduction of the animal a composition comprising warning the degradation of cartilage, effective and nontoxic amount of a combination of at least one sulfur-containing amino acids selected from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, DL-cystine, alpha-hydroxy analogue of methionine, beta-hydroxy analogue of methionine, manganese methionine, and mixtures thereof, and manganese.

8. The method according to claim 7, in which the animal is a dog or a cat.

9. The method according to claim 7, in which the sulfur-containing amino acid and margana the C are provided in the stern.

10. The method according to claim 9, in which the degradation of cartilage caused by an abnormality of cartilage selected from the group consisting of osteoarthritis, rheumatoid arthritis, degenerative disc disease, degenerative joint disease, synovitis, bacterial purulent arthritis and psoriatic osteoarthropathy.

11. The method according to claim 7, additionally comprising an introduction to the animal an effective amount of at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidants, green lipped canaliculata, fatty acids omega-3, omega-6 and mixtures thereof.

12. The method according to claim 7, additionally comprising an introduction to the animal a composition containing a warning of the degradation of cartilage, effective and non-toxic amount of at least glycine or Proline.

13. The composition is suitable for correcting pathological cartilage, reduce cartilage pathologies or preventing degradation of cartilage in animals containing reducing the pathology of cartilage or warning the degradation of cartilage, effective and nontoxic amount of a combination of at least one sulfur-containing amino acids selected from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, DL-cystine, alpha-hydroxy analogue of methionine, beta-hydroxy analogue of methionine, mation is and manganese, and their mixtures and manganese.

14. The composition according to item 13, additionally containing at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidants, green lipped canaliculata, fatty acids omega-3, omega-6 and mixtures thereof.

15. The composition according to item 13, additionally containing reducing the pathology of cartilage or warning the degradation of cartilage, effective and non-toxic at least glycine or Proline.

16. The composition according to item 13, additionally containing food suitable for consumption by an animal.

17. The composition according to item 16, further containing reducing the pathology of cartilage or warning the degradation of cartilage, effective and non-toxic at least glycine or Proline.

18. Set suitable for correction or reduction of cartilage pathologies, or preventing degradation of cartilage in animals, containing in separate containers in a single package or in separate containers in a virtual package, which corresponds to the component set, the first component set comprising at least one sulfur-containing amino acid or manganese, and the second component set comprising at least one compound of (1) sulfur-containing amino acids selected from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, D-cystine, alpha-hydroxy analogue of methionine, beta-hydroxy analogue of methionine, manganese methionine, and mixtures thereof, (2) manganese, (3) other sulfur-containing amino acids, (4) feed, suitable for animal consumption, (5) at least one substance selected from the group consisting of glucosamine, chondroitin, chondroitin sulfate, MSM, creatine, antioxidants, green lipped canaliculata, fatty acids omega-3, omega-6 and mixtures thereof, and (6) a means of sharing information or instructions for the treatment of diseases affecting cartilage, increase the flexibility of the cartilage, increasing the strength of the cartilage or prevent the degradation of cartilage in animals.

19. Set p, optionally containing one or more drugs that are suitable for the correction or reduction of cartilage pathologies or preventing degradation of the cartilage of the animal.

20. Set according to claim 19, in which medicines contain one or more of aspirin, ibuprofen and inhibitor SOH-2.

21. The use of a composition comprising a combination of at least one sulfur-containing amino acids selected from the group consisting of D-methionine, L-methionine, DL-methionine, D-cysteine, L-cysteine, DL-cysteine, D-cystine, L-cystine, DL-cystine, alpha-hydroxy analogue of methionine, beta-hydroxy analogue of methionine, manganese methionine, and mixtures thereof, and manganese for the manufacture of medicines to reduce cartilage pathologies or preventing degradation of cartilage in animals.



 

Same patents:

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a liquid pharmaceutical composition containing ionite bound Pradofloxacine, and filled ionite is dispersed in a carrier medium containing water and one or more structurally viscous gelling agents, and the elastic ratio of the composition makes 5 to 50 Pa, and also to application thereof for making a medical product.

EFFECT: compositions shows improved physical stability and provide available intake of the preparation by animals.

5 cl, 1 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a liquid pharmaceutical composition containing ionite bound Pradofloxacine, and filled ionite is dispersed in a carrier medium containing water and one or more structurally viscous gelling agents, and the elastic ratio of the composition makes 5 to 50 Pa, and also to application thereof for making a medical product.

EFFECT: compositions shows improved physical stability and provide available intake of the preparation by animals.

5 cl, 1 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medical products, particularly a liquid pharmaceutical composition containing ionite bound Pradofloxacine, and filled ionite is dispersed in a carrier medium containing water and one or more structurally viscous gelling agents, and the elastic ratio of the composition makes 5 to 50 Pa, and also to application thereof for making a medical product.

EFFECT: compositions shows improved physical stability and provide available intake of the preparation by animals.

5 cl, 1 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: present group of inventions concerns medicine, more specifically coated implants and devices. There is offered ceramic composition-precursor for making high-strength bio-elements used as an absorbable or partially absorbable biomaterial where the composition contains at least one silicate with Ca as a base cation with the absorption rate less or equal to the bone growth rate, and this at least one silicate acts as a base binding phase in a biomaterial, and this at least one silicate Ca is present in amount 50 wt % or more, and all other components if any are presented by additives, such as an inert phase, and/or additives which make a biomaterial to be radiopaque. There is offered hardened ceramic material which is based on the ceramic composition-precursor and is in the hydrated form. There is offered a medical implant, application of the medical implant, and also a device or a substrate coated with the uncured ceramic composition-precursor and/or hardened ceramic material.

EFFECT: invention provides a biomaterial having initial and constant durability which is dissolved in due time and reacts with an organism to generate a new tissue.

29 cl, 1 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, namely to pharmaceutical compositions for the oral medical products applied in the integrated treatment of menopause osteoporosis in women. There is offered pharmaceutical composition which contains one or more active substances mainly with different therapeutic modalities providing intensified osteogenesis or decreased bone resorption, an element-vitamin complex containing elements in the form of physiologically acceptable compounds, providing intensified bone formations and decreased bone resorption, and the vitamins intensifying therapeutic action of the active substances and ensuring intensified bone formation and decreased resorption, and an excipient in the form of one substance or mixed substances which is monoexcipient or one component of the excipient.

EFFECT: higher effectiveness of the composition.

6 cl, 13 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to transdermal plaster, which contains rasagiline, for treatment or prevention of nervous system diseases, where plaster contains inert supporting layer, which is chemically inert to substrate ingredients, substrate layer, which contains effective amount of rasagiline or its pharmaceutically acceptable salt, and protective layer, which is removed before application. Substrate layer represents adhesive system, which contains organic polymer material as base and inorganic or organic material as filler and many microreservoirs which contain rasagiline. Substrate additionally contains one or more substances for increase of transdermal absorption of rasagiline, where said organic polymer material in substrate is applied rasagiline reservoir and as binding substance.

EFFECT: increase of transdermal plaster efficiency.

14 cl, 18 dwg, 26 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention concerns pharmaceutical industry, particularly a pharmaceutical composition for treatment and prevention of diseases associated with disturbed antioxidant protection of organs and tissues, made in the tableted dosage form and containing green coffee berry extract, ascorbic acid and an excipient in certain component ratio.

EFFECT: described pharmaceutical composition is an effective remedy and can be applied in treatment and prevention of the majority of the diseases associated with disturbed antioxidant protection, including for treatment and prevention hepatic diseases, conditions of nervous, reproductive, cardiovascular systems, including for treatment and prevention of hyper- and hypotensive conditions, and also of diabetes types 1 and 2, including diabetic complications, - retinopathy, neuropathy, nephropathies, and metabolic syndrome.

3 cl, 7 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry. Trimetazidine preparation as a matrix tablet of prolonged action contains an active substance, montanic glycolic wax, polymer of methacrylic acid, hydrophilic polymer representing hydroxypropyl methylcellulose, microcrystalline cellulose, mannitol and adjuvants, in amounts specified in the patent claim. There is also disclosed method for making Trimetazidine preparation as a matrix tablet.

EFFECT: invention provides controlled prolonged release of Trimetazidine that leads to stable concentration level of the active substance.

10 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry. Trimetazidine preparation as a matrix tablet of prolonged action contains an active substance, montanic glycolic wax, polymer of methacrylic acid, hydrophilic polymer representing hydroxypropyl methylcellulose, microcrystalline cellulose, mannitol and adjuvants, in amounts specified in the patent claim. There is also disclosed method for making Trimetazidine preparation as a matrix tablet.

EFFECT: invention provides controlled prolonged release of Trimetazidine that leads to stable concentration level of the active substance.

10 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry. Trimetazidine preparation as a matrix tablet of prolonged action contains an active substance, montanic glycolic wax, polymer of methacrylic acid, hydrophilic polymer representing hydroxypropyl methylcellulose, microcrystalline cellulose, mannitol and adjuvants, in amounts specified in the patent claim. There is also disclosed method for making Trimetazidine preparation as a matrix tablet.

EFFECT: invention provides controlled prolonged release of Trimetazidine that leads to stable concentration level of the active substance.

10 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and immunology and concerns a conjugate for immunisation and vaccination and method for improving immunogenicity. Substance of the invention involves said conjugate for immunisation and vaccination representing an immunogen covalently bonded with a high-molecular carrier that is acidic peptidoglycane of molecular weight 1200-40000 KDa, and having the mass ratio of glucose and uronic acids 1:2-4.

EFFECT: advantage of the invention consists in improved immunogenicity 10-100 times higher, that in turn allows reducing immunogen doses in 10-100 times to achieve the same effect.

6 cl, 6 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to manufacturing of vaccines for intranasal introductions. There is offered composition to be delivered through mucous membrane, containing two or more following agents: a capsular oligosaccharide antigen which induces immune response on Haemophilus influenzae; and (b) a capsular oligosaccharide antigen which induces immune response on Neisseria meningitidis; with specified antigens conjugated with a carrier protein.

EFFECT: combination allows for single introduction to immunisation against two separate agents of the systemic disease, namely bacterial meningitis.

20 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and aims at treatment of cancer in an individual. It involves introduction to the specified individual of amount of purified heat-shock protein (HSP) preparation. The purified HSP preparation contains purified HSP-peptide complexes containing HSP covalently or non-covalently attached to peptide and where HSP-peptide complexes express antigenicity of said cancer. In addition, an immunogenic reagent is introduced to an individual, where the immunogenic reagent specifically reacts with antigen chosen from the group consisting of VEGF, EGF-R, HER2/NEU, CD25 and CD20, or is being anti-CTLA-4 or anti 41BB antibody.

EFFECT: combined introduction of HSP-peptide complexes and immunogenic reagent allows intensifying immune response in antibody therapy of cancer.

36 cl, 4 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine and Fc-erythropoietin fused protein with improved pharmacokinetics. Invention claims novel sialylated Fc-EPO fused proteins preferably including modification pair in Fc part, as well as in EPO part, showing improved pharmacokinetics. Particularly, Fc-EPO proteins have longer half-life in blood serum and higher efficiency in vivo. Fc-EPO fused proteins synthesised in BHK cells show much longer half-life in blood serum and higher efficiency in vivo than similar Fc-EPO fused proteins obtained in other cell lines, such as NS/0 cells.

EFFECT: improved pharmacokinetic properties of erythropoietin.

23 cl, 14 ex, 6 tbl, 11 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicines, particularly to the use of chimeric peptide VP-22_p16INK4a for epithelial and mesenchymal malignant neoplasms treatment. The claimed chimeric peptide VP-22_p16INK4a contains two amino acid sequences. The first sequence comprises inhibitor of cycline kinases as active fragment p16INK4a as therapeutic agent and the second sequence comprises peptide VP22 of herpes simplex virus as carrier agent to deliver cycline kinase inhibitor into target cells.

EFFECT: enlarging the application range of medicine.

9 dwg

FIELD: medicine.

SUBSTANCE: invention concerns area of medicine and concerns compositions and medicinal forms on the basis of Gastrinum, application and reception methods. The essence of the invention includes the bond of Gastrinum representing conjugates of fragments of amino-acid sequence of Gastrinum, possessing functional ability to contact Gastrinum/SSK receptor, with various carriers, including application amino-acid spacers, and application of bifunctional sewing agents, and also a method of treatment by the compositions including bond of Gastrinum, sick of diabetes.

EFFECT: advantage of the invention consists in action prolongation.

7 cl, 8 ex, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns vaccines, particularly vaccines for meningococcal infections and diseases. Invention claims immunogenic composition for transport via mucosa, including capsular saccharides of at least two of the following serological groups: A, C and W135 and Y N. Meningitidis, as well as trialkylated chitosan.

EFFECT: enhanced production of immune response to meningococci in mucosa, possible balance shift of Th1/Th2 type responses.

16 cl, 24 dwg

FIELD: chemistry.

SUBSTANCE: invention pertains to modified polysaccharide in particular to modified polysaccharide Neisseria meningitidis of serogroup A, which preserves immunogenicity, but has improved stability. The modified polysaccharide is obtained from reaction of capsular polysaccharide, or its fragment - oligosaccharide, with CDI type bifunctional reagent, accompanied by reaction with an amino-compound, such as dimethylamine. Description is also given of modified polysaccharide conjugates and vaccines, which are obtained from such conjugates.

EFFECT: obtaining modified saccharide.

70 cl, 17 dwg

FIELD: medicine; veterinary science.

SUBSTANCE: method of higher meat production of broilers provides single injection for day birds of liposomal forms of preparation containing chimeric protein with water insoluble enzyme-inactive chloramphenicol acetyltransferase without 10 S-terminal aminoacids, aminoacid spacer (Sp)n, where n=1, 2, 4, 8 and somatostatin-14 with aminoacid sequence AGCFWKTFTSC, with median size of liposomes 250±50 nm. And preparation is introduced in combination with Marek's disease factor vaccine.

EFFECT: invention allows for higher effective meat production of broilers using single injection of preparation during the whole fattening period.

2 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention concerns aldehyde derivatives and conjugates of di-, oligo- or polysaccharide, of the general formula (I), methods of obtaining them, and pharmaceutical composition based on them and capable of staying in blood flow for prolonged time. , where R is -CH(CHO)CH2OH, -CH2CHO, -CH(CH2NHR1)CH2OH, -CH(CH2NHNHR1)CH2OH, -CH(CH=NNHR1)CH2OH, -CH2CH2NHR1, -CH2CH=N-NHR1, -CH2CH2NHNHR1; R1 is polypeptide or albumen; GlyO is a sialic acid bond; R3 is H; R4 is OH; n is 2 or more.

EFFECT: obtaining pharmaceutical composition based on aldehyde derivatives of sialic acid capable of staying in blood flow for prolonged time.

20 cl, 7 tbl, 22 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical unit dosage form for treatment or prevention of cardiovascular episodes contains therapeutic amount of: antagonist of β-adrenergic receptor, diuretic or both; an agent lowering cholesterol level; an inhibitor of renin-angiotensin system; and aspirin. The pharmaceutical unit dosage form can be made in a two-layered tableted form. The first layer thereof contains simvastatin and aspirin, the second layer contains athenolol and lisinopril, or the second layer contains hydrichlorothiazide and lisinopril.

EFFECT: according to the invention pharmaceutical unit dosage form combines a number of drugs for oral intake once a day that improves compliance by the patient with prescribed regimen due to elimination of inconveniences related to intake of several doses of drugs during the day, and reduces probability of missing the dose.

24 cl, 5 ex

Up!